List of Excipients in Branded Drug AMABELZ

Generic Drugs Containing AMABELZ

Company	Ingredient	NDC	Excipient
Lupin Pharmaceuticals Inc	estradiol and norethindrone acetate	68180-830	COPOVIDONE K25-31
Lupin Pharmaceuticals Inc	estradiol and norethindrone acetate	68180-830	HYPROMELLOSES
Lupin Pharmaceuticals Inc	estradiol and norethindrone acetate	68180-830	LACTOSE MONOHYDRATE
Lupin Pharmaceuticals Inc	estradiol and norethindrone acetate	68180-830	MAGNESIUM STEARATE
Lupin Pharmaceuticals Inc	estradiol and norethindrone acetate	68180-830	STARCH, CORN
Lupin Pharmaceuticals Inc	estradiol and norethindrone acetate	68180-830	TRIACETIN

What are the Most Frequently-Used Excipients in AMABELZ?

# Of NDCs	Excipient
1	COPOVIDONE K25-31
1	HYPROMELLOSES
1	LACTOSE MONOHYDRATE
1	MAGNESIUM STEARATE
1	STARCH, CORN
1	TRIACETIN

AMABELZ Excipient Strategy and Commercial Opportunities

Last updated: August 16, 2026

Amabelz is an oral combination hormone-replacement tablet containing estradiol and norethindrone acetate. Its commercial opportunity is primarily in lifecycle reformulation, supply-chain optimization, generic substitution, and differentiated menopause products rather than in a new-molecule patent strategy. The most practical excipient programs are low-risk tablet robustness, dose-uniformity improvement, stability enhancement, patient acceptability, and development of alternative estrogen-progestin presentations.

What is Amabelz and which excipients does it contain?

Amabelz is an immediate-release, film-coated tablet available in two strengths:

Product strength	Estradiol	Norethindrone acetate	Therapeutic role
Amabelz 0.5 mg/0.1 mg	0.5 mg	0.1 mg	Lower-dose menopausal hormone therapy
Amabelz 1 mg/0.5 mg	1 mg	0.5 mg	Standard-dose menopausal hormone therapy

The product is indicated for treatment of moderate-to-severe vasomotor symptoms and vulvar and vaginal atrophy associated with menopause. In women with an intact uterus, the progestin component reduces the risk of endometrial hyperplasia associated with systemic estrogen therapy.[1]

Public labeling identifies Amabelz as a film-coated tablet. The inactive ingredients include standard oral solid-dose excipients such as lactose monohydrate, microcrystalline cellulose, starch-related disintegrant or binder materials, povidone, magnesium stearate, hypromellose, titanium dioxide, talc and polyethylene glycol. Exact excipient composition can vary by strength and manufacturing site and should be confirmed against the current FDA label and DailyMed record before regulatory filing or competitive benchmarking.[1,2]

The formulation challenge is unusual for a conventional tablet: both active ingredients are present at low dose, particularly norethindrone acetate in the 0.5 mg/0.1 mg strength. The excipient system must support blend uniformity, content uniformity, compactibility, dissolution and long-term chemical stability without creating excessive tablet weight or manufacturing complexity.

How does Amabelz compare with competing menopause products?

Amabelz competes with oral estradiol/norethindrone acetate products, other estrogen-progestin combinations, estrogen-only products and transdermal hormone therapies.

Product category	Estrogen component	Progestin component	Typical commercial differentiation
Amabelz	Oral estradiol	Norethindrone acetate	Generic combination tablet; low manufacturing cost
Activella	Oral estradiol	Norethindrone acetate	Reference-brand positioning and historical physician familiarity
Bijuva	Oral estradiol	Micronized progesterone	Branded bioidentical hormone combination
Prempro	Conjugated estrogens	Medroxyprogesterone acetate	Established branded combination
Annovera and other vaginal systems	Ethinyl estradiol or other hormonal actives	Product-specific progestin	Long-acting or local delivery models
Estradiol patches plus oral progesterone	Transdermal estradiol	Separate micronized progesterone or other progestin	Lower hepatic first-pass exposure and regimen flexibility

Amabelz has a cost advantage over branded products but limited formulation differentiation. The principal commercial vulnerability is substitution by lower-cost generics, authorized generics, alternative combination products and clinicians’ preference for transdermal estradiol or micronized progesterone.

A differentiated excipient strategy must therefore create a measurable benefit, such as improved stability, smaller tablets, reduced lactose exposure, better swallowability, enhanced tablet mechanical strength or a formulation compatible with a new dosage form.

What excipient functions are most important in Amabelz tablets?

Content uniformity at low active concentrations

The 0.5 mg/0.1 mg presentation contains a particularly low quantity of norethindrone acetate. Segregation during blending, transfer or compression can create content-uniformity risk. Excipient selection should focus on particle-size matching and controlled powder flow rather than simply increasing binder concentration.

Potential approaches include:

• Co-milling or particle-size engineering of the active ingredients.
• Ordered mixing using carrier particles.
• Roller compaction when direct compression produces segregation.
• Use of a highly functionalized microcrystalline cellulose.
• Low-dose premixes or geometric dilution.
• Inline blend monitoring using near-infrared spectroscopy.

A premix or co-processed excipient system could have commercial value if it improves uniformity without changing dissolution or increasing tablet size. The strongest intellectual-property position would generally be a defined composition combined with a manufacturing process and performance limits, rather than a broad claim to a common excipient.

Compression and tablet robustness

Estradiol and norethindrone acetate are low-dose hormonal actives. The tablet therefore depends heavily on excipients for mass, strength and handling performance.

Relevant excipient variables include:

• Microcrystalline cellulose grade and particle morphology.
• Lactose particle size and flow properties.
• Pregelatinized starch or crospovidone level.
• Povidone molecular weight and binder concentration.
• Magnesium stearate concentration and lubrication time.
• Compression force and dwell time.
• Granulation endpoint and residual moisture.

Over-lubrication can reduce tablet tensile strength and slow dissolution. Excessive binder can delay disintegration. Excess disintegrant can increase friability or create variable dissolution after storage. A design-of-experiments program should link formulation variables to tensile strength, friability, disintegration, dissolution, assay, content uniformity and degradation products.

Chemical stability

Estradiol and norethindrone acetate require protection against heat, moisture, oxygen and light. Film coating and packaging are central to product stability.

Commercially relevant excipient interventions include:

• Low-moisture filler systems.
• Reduced-peroxide grades of povidone and crospovidone.
• Antioxidant screening where compatible with the product and regulatory justification.
• Moisture-barrier film coatings.
• Opacifying pigments for light protection.
• Desiccant-containing bottles.
• High-barrier blister packaging.

Excipient suppliers can capture value by offering qualified low-peroxide polymers, low-moisture excipients and validated coating systems. These materials may improve stability without creating a clinically meaningful change in the product.

What formulation patents could protect an Amabelz lifecycle product?

A conventional Amabelz tablet is unlikely to support strong exclusivity from generic use of lactose, cellulose, povidone or magnesium stearate alone. A commercially meaningful formulation patent would need a defined technical result.

Potential claim areas include:

1. Low-dose uniformity composition. A tablet containing specified particle-size distributions, excipient ratios and content-uniformity limits for estradiol and norethindrone acetate.

2. Moisture-controlled formulation. A composition using defined low-moisture excipients and packaging that reduces impurity growth during accelerated or long-term storage.

3. Modified-release oral formulation. A controlled-release or delayed-release system designed to alter exposure or dosing frequency. This would require new pharmacokinetic and clinical support.

4. Orally disintegrating tablet. A fast-disintegrating formulation for patients with dysphagia. Taste masking, dose uniformity and hormone handling would be key development issues.

5. Multiparticulate capsule. Separate or combined pellets could improve dose flexibility and allow independent release profiles for estradiol and norethindrone acetate.

6. Fixed-dose tablet with improved swallowability. A smaller, higher-density tablet or mini-tablet system could support a patient-centered lifecycle product.

7. Alternative excipient-free or reduced-excipient composition. This may address lactose intolerance, excipient sensitivity or supply-chain constraints, although it must demonstrate equivalent performance.

The strongest patent package would combine composition claims, process claims, dissolution or stability limitations and a method-of-use claim where legally available. A generic manufacturer should expect design-around activity if the patent depends only on routine excipient substitutions.

When does Amabelz lose exclusivity?

Amabelz is a generic product rather than a new chemical entity. The principal commercial barriers are therefore regulatory approval, bioequivalence, manufacturing quality, product availability and any remaining listed patents associated with the reference product.

FDA generic products may receive 180-day exclusivity when they are eligible first applicants that submit a Paragraph IV certification and satisfy the statutory requirements. Later applicants may enter after the relevant exclusivity period, litigation resolution or patent expiration. FDA’s Orange Book identifies listed patents and regulatory exclusivity for approved products.[3]

For Amabelz, the relevant review should distinguish:

• Patent protection associated with the reference product.
• Any patents listed for the specific estradiol/norethindrone acetate product.
• Regulatory exclusivity, if any.
• Litigation settlements affecting commercial launch.
• Current ANDA approvals and market status.

No active formulation-patent conclusion should be drawn solely from the brand name. Patent and Paragraph IV status must be verified in the current Orange Book, FDA approval records and USPTO or court records. The marketed product’s commercial exposure is more likely to reflect generic competition and reimbursement pressure than a single blocking patent.

What FDA regulatory pathway applies to an Amabelz reformulation?

A reformulated version that is pharmaceutically equivalent and bioequivalent to the reference product can generally be pursued through an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. FDA’s product-specific guidance, labeling requirements and dissolution expectations determine whether the proposed excipient change remains within the ANDA framework.[4]

A formulation that changes release characteristics, dosage form, route of administration or clinical performance may require a different pathway, including a 505(b)(2) application. This route can be appropriate for:

• An orally disintegrating tablet.
• A modified-release product.
• A transdermal estradiol/norethindrone system.
• A vaginal or buccal delivery product.
• A product with a new dosing regimen or clinical use.

Excipient changes in an ANDA typically require comparative dissolution and stability evidence. Depending on the change, FDA may also expect additional bioequivalence work. The formulation must comply with FDA’s Inactive Ingredient Database limits and applicable USP-NF standards.[5,6]

What commercial opportunities exist for excipient suppliers?

Low-peroxide and low-moisture excipients

Suppliers can target manufacturers seeking improved impurity control and shelf life. The opportunity is strongest for povidone, crospovidone, starches and other materials that may contribute peroxide or moisture variability.

Co-processed direct-compression systems

A co-processed filler-binder-disintegrant system could reduce blending complexity and improve tablet robustness. The value proposition is manufacturing consistency, particularly for low-dose products with narrow content-uniformity margins.

Film-coating platforms

A ready-to-use coating system with controlled moisture permeability, light protection and efficient processing could support Amabelz and comparable hormone tablets. A coating platform can be commercialized across multiple strengths and products.

Barrier packaging

High-barrier blister materials, desiccant bottles and unit-dose packaging can address stability and adherence. Calendar blister packs may support cyclic hormone regimens and reduce missed doses.

Excipient qualification and dual sourcing

Hormone products can face supply risk from specialized active pharmaceutical ingredients and low-volume manufacturing. Dual-source excipient programs, supplier audits and change-control packages can reduce regulatory and commercial disruption.

Patient-centered dosage forms

Smaller tablets, orally disintegrating tablets and flexible-dose multiparticulates are the most credible lifecycle opportunities. These products require more development than a conventional excipient substitution but can generate differentiation in a crowded generic market.

How strong is the patent opportunity for Amabelz excipient innovation?

The patent opportunity is moderate for a technically defined reformulation and weak for routine substitution of established excipients.

Innovation type	Patent potential	Regulatory burden	Commercial value
Substitute lactose grade	Low	Low	Low
Low-peroxide excipient system	Moderate	Low to moderate	Moderate
Co-processed low-dose blend	Moderate to high	Moderate	Moderate to high
Moisture-protective coating	Moderate	Low to moderate	Moderate
Smaller tablet	Moderate	Moderate	Moderate
Orally disintegrating tablet	Moderate to high	High	High if clinically useful
Modified-release product	High	High	High but uncertain
Transdermal combination	High	High	High, with significant development cost

Patent strength improves when the invention produces unexpected stability, dissolution, bioequivalence or manufacturing results. Claims limited to commercially interchangeable excipients are easier to challenge and design around.

What generic launch risks exist for Amabelz?

Generic launch risks include:

• Failure to demonstrate content uniformity for the low-dose strength.
• Dissolution changes caused by lubricant, binder or disintegrant variation.
• Degradation during accelerated stability testing.
• Inadequate control of peroxide or elemental impurities.
• Manufacturing segregation during scale-up.
• Excipient supplier changes after approval.
• Bioequivalence failure for a reformulated product.
• Patent or regulatory exclusivity identified in the current Orange Book.
• Physician movement toward transdermal estrogen or micronized progesterone products.
• Price erosion after additional ANDA approvals.

The most important development controls are blend uniformity, discriminatory dissolution, impurity profiling, moisture control and process validation at commercial scale.

What is the investment case for Amabelz excipient programs?

The near-term opportunity is a lower-cost, lower-risk improvement to the existing tablet platform. The strongest business case is likely to come from:

1. Improving manufacturing yield and reducing batch failures.
2. Extending shelf life or reducing packaging cost.
3. Creating a smaller or easier-to-swallow tablet.
4. Establishing a differentiated 505(b)(2) product with a new dosage form.
5. Supplying qualified excipients across multiple hormone-therapy products.

Revenue exposure is linked to product volume, payer substitution and the number of approved generic competitors. A conventional Amabelz tablet has limited pricing power. A differentiated dosage form can support higher pricing, but its value depends on clinical utility, reimbursement and the ability to obtain meaningful market exclusivity.

Key Takeaways

• Amabelz is an oral estradiol/norethindrone acetate combination tablet in 0.5 mg/0.1 mg and 1 mg/0.5 mg strengths.
• Low-dose content uniformity, compression, dissolution and stability are the main excipient-performance priorities.
• Low-peroxide polymers, low-moisture fillers, co-processed excipients and barrier coatings are the most practical near-term opportunities.
• Routine excipient substitution is unlikely to create strong patent protection.
• A smaller tablet, orally disintegrating tablet, multiparticulate system or modified-release product offers greater differentiation but increases regulatory cost.
• FDA pathway selection depends on whether the change remains pharmaceutically equivalent and bioequivalent or creates a new dosage form or release profile.
• Current Orange Book, FDA and litigation records must control any conclusion on patents, Paragraph IV challenges, exclusivity or launch timing.
• The commercial opportunity is stronger in manufacturing efficiency and differentiated lifecycle products than in a conventional generic tablet.

FAQs

Can lactose be removed from Amabelz?

Yes, a lactose-free formulation could be developed using alternative fillers such as microcrystalline cellulose, mannitol or selected dibasic calcium phosphate grades. The change would require evaluation of content uniformity, dissolution, stability, tablet size and bioequivalence requirements.

Is an Amabelz transdermal formulation commercially attractive?

Potentially. A transdermal estradiol/norethindrone product could address interest in nonoral estrogen delivery, but it would require adhesive, permeation, residual-drug, skin-tolerability and clinical development work. It would be a new product strategy rather than a simple Amabelz excipient change.

Which excipient is most important for low-dose norethindrone acetate uniformity?

The most important factor is the complete powder-engineering system, including particle-size matching, premixing, carrier selection, blending energy and transfer control. No single excipient reliably solves segregation across all manufacturing processes.

Can an excipient supplier obtain patent protection for an Amabelz tablet?

Yes, but the claim must generally cover a defined formulation or process with measurable technical advantages. A patent directed only to replacing one conventional filler with another is likely to have limited defensibility.

Does Amabelz have biosimilar competition?

No. Amabelz contains chemically synthesized small-molecule hormones, not a biologic. Competition arises through generic drug approvals, alternative combination products and other estrogen or progestin delivery systems rather than the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (n.d.). Amabelz (estradiol and norethindrone acetate) tablets: Prescribing information.

2. National Library of Medicine. (n.d.). DailyMed: Amabelz, estradiol and norethindrone acetate tablet, film coated.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.

4. U.S. Food and Drug Administration. (2019). ANDA submissions: Content and format of an ANDA. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. Center for Drug Evaluation and Research.

6. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary, USP-NF.